Mycophenolate mofetil

DB00688ApprovedInvestigationalSmall moleculeAntimetabolite ImmunosuppressantImmunosuppressive Agents

Mycophenolate mofetil is an inosine monophosphate dehydrogenase inhibitor used to prevent the rejection of kidney, heart, or liver transplants. Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH).

Chemical structure of Mycophenolate mofetil
Mechanism
Curator reviewed · 7 references
Primary indication
Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old.Curator reviewed · 3 structured indications
Formula / weight
C23H31NO7 · 433.4947 g/mol (avg)
First approval
Canada, 1995 · United States, 1995 · European Union, 2016
Also known as
Mycophenolic acid morpholinoethyl ester
Code names
168396 · RS-61443
Brand names
  • Cellcept
  • Myclausen
  • Myfenax
  • Myhibbin

Resolves to

Structure
InChIKeyRTGDFNSFWBGLEC-SYZQJQIISA-NSMILESCOC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C

What you can answer from here — as of September 23, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
5TransportersSubstrate / inhibitor direction, not just membership
Listed above
1,791Drug interactionsStructured to mechanism, not free text
Sign in
818Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
3ContraindicationsEach with its own population and attribute set
Sign in
483Marketed productsAcross 11 countries and 118 labellers
Sign in
66+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Mycophenolate mofetil, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account